SequelSEC

Inhibitor Therapeutics, Inc. INTI

Pharmaceutical Preparations · CIK 0001042418 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2021-12-31
Operating income
-$325.40K
Fiscal year ended 2021-12-31
Free cash flow
Unavailable
Fiscal year ended 2021-12-31

Inhibitor Therapeutics, Inc. (INTI) reported revenue of $0 and net income of -$298.63K for the fiscal year ended 2021-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Inhibitor Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Inhibitor Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$325.40K-$1.06M-$2.75M-$4.56M-$5.12M-$7.02M-$3.95M-$3.94M
Net income-$298.63K-$1.06M-$2.73M-$4.55M-$5.10M-$7.00M-$3.95M-$3.98M
Research & development$4.90K$185.29K$1.21M$2.63M$2.23M$2.64M$1.68M$2.43M
Weighted-average diluted sharesshares 376.25MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$298.63KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0
Diluted EPS$0.00UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$320.49K$873.70K$1.54M$1.93M$2.89M$4.38M$2.27M$1.51M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Inhibitor Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$30.63K$75.06K$803.82K$1.11M$344.11K$6.89M$601.44K$365.16K
Total assets$58.78K$131.76K$899.97K$1.23M$768.05K$7.34M$885.86K$462.98K
Current assets$58.78K$107.35K$846.27K$1.15M$655.77K$7.20M$635.86K$462.98K
Total liabilities$3.68M$3.49M$3.43M$1.20M$601.49K$308.13K$461.88K$400.90K
Current liabilities$679.63K$425.41K$431.10K$700.65K$601.49K$308.13K$461.88K$400.90K
Total equity incl. NCI-$3.62M-$3.36M-$2.53M$32.35K$166.56K$7.03M$423.98K$62.08K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$279.84K$269.42K$315.94K$384.83K$534.96K$297.83K$383.36K$324.97K

Cash flow

Inhibitor Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$220.43K-$825.36K-$2.71M-$3.71M-$2.91MUnavailableUnavailableUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$176.00K$96.60K$2.40M$4.47M-$3.63MUnavailableUnavailableUnavailable
Net change in cash-$44.43K-$728.76K-$304.90K$764.60K-$6.54M$6.28M$236.28K$364.94K
Stock-based compensation$37.99K$228.86K$269.92K$543.10K$1.87M$3.56M$1.72M$753.58K
Common dividends paidUnavailable$0$99.18KUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Inhibitor Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.09x0.25x1.96x1.64x1.09x23.36x1.38x1.15x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INTI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.